For the treatment of tauopathy in AD and FTD, peptide-based PROTACs for tau such as TH006, which contains a tau recognition sequence (YQQYQDATADEQG), short linker, VHL recruit motif, and cell-penetrating poly-Arg region, were initially constructed and decreased the tau levels in the cells and the brains of an AD mouse model (Chu et al., 2016). This evidence concerns the gene MAPT and frontotemporal dementia.